Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

In an announcement on Monday, Illumina Inc. (NASDAQ: ILMN) said it will pay £6.25 billion in cash and stock to buy Grail Inc.

Illumina expresses plans of acquiring Grail Inc. for £6.25 billion

Illumina's news of its $8 billion deal to acquire Grail, a healthcare company focused on cancer detection, has ILMN stock down on Monday.

Illumina News: ILMN Stock Slides Lower on $8 Billion Grail Deal

Grail's blood test for early detection of 50 types of cancer is poised for launch next year.

Illumina to Acquire Cancer Diagnostics Start-up Grail

Cancer detection startup Grail will be acquired by DNA sequencing machine maker Illumina for $8 billion, the companies announced Monday.

Illumina will pay $8B to acquire Grail, the Bill Gates and Jeff Bezos-backed cancer detection company

Biotech firm Illumina will buy back cancer-detection startup Grail in an $8 billion deal that will buy out investors including Amazon chief Jeff Bezos, the companies said Monday. The deal — announced less than two weeks after Grail filed for an initial public offering — will give Illumina access to Galleri, a medical test that.

Biotech firm Illumina buying Jeff Bezos-backed startup Grail for $8 billion

Gene sequencing company Illumina will pay $8 billion in cash and stock to buy cancer screening startup Grail, the companies said.

Illumina buys Jeff Bezos-backed cancer-testing firm Grail in deal worth $8 billion

Illumina Inc. (NASDAQ: ILMN) shares dipped early Monday after the company announced that it would be making a critical acquisition.

What This Acquisition Adds to Illumina

Biotech has become one of the hottest areas of venture investment in recent years, as progress in machine learning, genetics, medical devices, and biology fuse together into new products for the gargantuan health industry. Case in point: Grail, which began in 2016 as a spinoff from genetic sequencing giant Illumina and co-founded by longtime Google […]

Illumina buying cancer-screening spinout Grail in blockbuster $8B biotech deal

Illumina announced an agreement to acquire its 2016 spinoff Grail, which makes a platform for early cancer detection, but analysts balked at the $8 billion price tag and Illumina stock fell.
The post Illumina Announces $8 Billion Acquisition Of Former Cancer-Testing Spinoff Grail appeared first on Investor's Business Daily.

Illumina Announces $8 Billion Acquisition Of Former Cancer-Testing Spinoff Grail

Shares of Illumina Inc. ILMN, -0.84% dropped 5.3% in premarket trading Monday, after the gene sequencing company confirmed a deal to buy Grail Inc.

Illumina's stock falls after $8 billion deal to buy Grail confirmed

SAN DIEGO & MENLO PARK, Calif.--(BUSINESS WIRE)---- $ILMN #ILMN--Illumina, Inc. (NASDAQ: ILMN) and GRAIL, a healthcare company whose mission is focused on multi-cancer early detection, today announced they have entered into a definitive agreement under which Illumina will acquire GRAIL for cash and stock consideration of $8 billion upon closing of the transaction. In addition, GRAIL stockholders will receive future payments representing a tiered single digit percentage of certain GRAIL-related revenues. The ag

Illumina to Acquire GRAIL to Launch New Era of Cancer Detection

Gene sequencing company Illumina Inc will pay $7.1 billion in cash and stock to buy cancer test startup Grail Inc, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Illumina to pay $7.1 billion for cancer test developer Grail: WSJ

Illumina’s stock dropped nearly 15% in the last 5 trading days while the S&P 500 barely moved. It appears more of a market correction driven by profit taking, considering that the stock has gone up this year despite shrinking sales.

Biotech Firm Illumina Fell 15% In 5 Days – Should You Sell?

Shares of Illumina Inc. ILMN, -0.84% dropped 2.7% in premarket trading Monday, after the gene sequencing company has struck a deal to pay $7.1 billion in cash and stock to buy the part of Grail Inc.

Illumina's stock falls after WSJ report of $7.1 billion cash and stock deal to buy Grail

Illumina is rumoured to be in talks with oncology testing company Grail over a potential $8bn bid.

Deal Or No Deal, Grail Is Not The Endgame For Illumina - Investors Can Think Bigger

Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.

Illumina-CDGN Partner to Create Coronavirus Tracking System

A week after filing for an initial public offering with the Securities and Exchange Commission, reports are suggesting that the cancer detection startup Grail Inc.

Illumina In Talks To Acquire Cancer Startup Backed By Jeff Bezos, Bill Gates At $8B: Report

Report: Illumina in Talks to Acquire Cancer Diagnostics Startup Grail

Shares of Illumina Inc. ILMN, -6.76% tumbled 6.3% in trading on Wednesday after Bloomberg reported that the company is in talks to acquire Grail Inc.

Illumina's stock falls after Bloomberg reports it is considering acquisition of Grail Inc.

In a growing industry, a company with a head start can produce outsized returns for shareholders.

Is This Company the Tesla of Gene Sequencing?

Illumina, best known for its genetic variation and biological function systems, has rallied 46% since late March (vs. about 55% for the S&P 500) to its current level around $347.

How Does Illumina Stock Performance In 2020 Compare With That During 2008 Crisis?

Exelixis

Vertex Pharmaceuticals

The long-term picture is bright for these healthcare stocks thanks to stable product revenue.

Got $5,000? 3 Surefire Stocks to Buy Ahead of the Next Market Crash

BioMarin Pharmaceutical

Cameco

PFSweb

Toxic stocks are sure to result in loss for investors over time. Figuring out such stocks on a consistent basis and discarding them at the right time is the key to successful investing.

These 4 Stocks Could Be Toxic for Your Portfolio

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock?

Why Is Illumina (ILMN) Down 14.3% Since Last Earnings Report?

The stock price of Illumina, best known for its genetic variation and biological function systems, has seen a 3x growth since the end of 2017. But how did the company pull off such impressive gains, as its revenues grew 45% over the same period?

News for Illumina Stock (ILMN)